PHV-wordings
Paracetamol
Additional template
|
25/03/2022
Further information is available in the CMDh press release (Report from the meeting held on 25-27 January 2022) on the HMA-Website.
Pholcodine
Additional template
|
24/03/2022
Further information is available in the CMDh press release (Report from the meeting held on 25-27 January 2022) on the HMA-Website.
Lactulose
PSUR-outcome
|
24/03/2022
Further information and amendments to the product information in all EU languages are available on the EMA website.
Pholcodine
PSUR-outcome
|
22/03/2022
Further information and amendments to the product information in all EU languages are available on the EMA website.
Loperamide, Loperamide/Simeticone
PSUR-outcome
|
22/03/2022
Further information and amendments to the product information in all EU languages are available on the EMA website.
Levonorgestrel (all indications except emergency contraception)
PSUR-outcome
|
22/03/2022
Further information and amendments to the product information in all EU languages are available on the EMA website.
Remifentanil
PSUR-outcome
|
18/03/2022
Further information and amendments to the product information in all EU languages are available on the EMA website.
Paracetamol (IV formulation)
PSUR-outcome
|
18/03/2022
Further information and amendments to the product information in all EU languages are available on the EMA website.
Tacrolimus (systemic formulations)
PSUR-outcome
|
25/02/2022
Further information can be found in the Commission Decision and its annexes, which are available in all EU languages on the European Commission's (EC) website.
Mycophenolate mofetil or Mycophenolic acid
PSUR-outcome
|
24/02/2022
Further information can be found in the Commission Decision and its annexes, which are available in all EU languages on the European Commission's (EC) website.
